Abstract Purpose: HumanTcells targeted to the B cell^specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1, have shown significant but partial in vivo antitumor efficacy in a severe combined immunodeficient (SCID)-Beige systemic human acute lymphoblastic leukemia (NALM-6) tumor model. Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy. Experimental Design: A panel of modified CD19-targeted CARs designed to deliver combined activating and costimulatory signals to theT cell was generated and tested in vitro to identify an optimal second-generation CAR. Antitumor efficacy of Tcells expressing this optimal costimulatory CAR, 19-28z, was analyzed in mice bearing systemic costimulatory ligand-deficient NALM-6 tumors. Results: Expression of the 19-28z CAR, containing the signaling domain of the CD28 receptor, enhanced systemic T-cell antitumor activity when compared with 19z1 in treated mice. A treatment schedule of 4 weekly T-cell injections, designed to prolong in vivo T-cell function, further improved long-term survival. Bioluminescent imaging of tumor in treated mice failed to identify a conserved site of tumor relapse, consistent with successful homing by tumor-specific T cells to systemic sites of tumor involvement. Conclusions: Both in vivo costimulation and repeated administration enhance eradication of systemic tumor by genetically targeted T cells. The finding that modifications in CAR design as well asT-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.
The majority of adult B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non -Hodgkin's lymphoma, are incurable despite currently available therapies. For this reason, novel therapeutic strategies are needed to treat these diseases. Adoptive therapy with genetically engineered autologous T cells is one such approach. T cells may be modified to target tumor-associated antigens through the introduction of genes encoding artificial T-cell receptors, termed chimeric antigen receptors (CAR), specific to such antigens (1 -5) .
CD19 is an attractive target for immune-mediated therapies as it is expressed on most B-cell malignancies and normal B cells, but not on bone marrow stem cells. We previously constructed a ''first-generation'' CAR, termed 19z1, specific to the CD19 antigen. The 19z1 CAR contains a CD19-specific murine single-chain fragment length antibody (scFv) fused to the extracellular and transmembrane regions of CD8, which, in turn, is fused to the intracellular signaling domain of the CD3c hain. Human T cells retrovirally transduced to express the 19z1 receptor specifically lyse heterologous and autologous CD19 + human tumor cells in vitro (6) . A single i.v. injection of 19z1 + T cells into SCID-Beige mice bearing established systemic Raji tumor, a human Burkitt lymphoma tumor cell line that expresses the costimulatory ligands CD80 and CD86, successfully eradicates disease in 50% of mice (6) . Unfortunately, a similar therapy fails to fully eradicate systemic NALM-6 tumor, a human pre-B cell ALL cell line that lacks expression of both CD80 and CD86. However, 19z1 + T-cell therapy of SCID-Beige mice bearing systemic NALM-6 tumors genetically engineered to express CD80 (NALM-6/CD80) enhanced long-term survival and resulted in complete NALM-6/CD80 tumor eradication in 40% of mice (6) . Although these data show a role for in vivo costimulation in tumor eradication by genetically modified tumor-targeted T cells, they neither fully explain the etiologies of treatment failure in a majority of treated mice nor provide a strategy to overcome these limitations.
To further investigate the in vivo limitations of this adoptive T-cell strategy, we chose to pursue the treatment of NALM-6 tumors in SCID-Beige mice due to the fact that the tumor in this model has several features that mimic B-cell ALL disease in human subjects: First, the disease is systemic; second, similar to the clinical setting, NALM-6 tumor displays an anatomic disease pattern that includes involvement of the bone marrow and central nervous system (CNS; ref. 7) ; and third, the NALM-6 tumor cell line fails to express costimulatory ligands as do most B-cell leukemias, including B-cell ALL. In this report, we use this NALM-6 tumor model to address the limitation of failed in vivo T-cell costimulation, and further investigate T-cell persistence and homing as potential etiologies of treatment failure. We found that both in vivo costimulation as well as repeated T-cell administration were critical to the complete eradication of NALM-6 tumor in SCID-Beige mice. Subsequent modifications in our treatment strategy based on these findings resulted in a markedly improved rate of complete tumor eradication in treated mice.
To our knowledge, this is the first report demonstrating complete eradication of a systemic human tumor lacking costimulatory ligands using genetically targeted T cells. Furthermore, complete eradication is achieved in the absence of further in vivo therapy, including prior chemotherapy or subsequent cytokine support. These optimized treatment strategies are likely to be applicable to future human trials enrolling patients with B-cell malignancies, including B-cell ALL.
Materials and Methods
Cell lines and T cells. Raji and NALM-6 tumor cell lines were cultured in RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated FCS, nonessential amino acids, HEPES buffer, pyruvate, and BME (Life Technologies). PG-13 and gpg29 retroviral producer cell lines were cultured in DMEM (Life Technologies) supplemented with 10% FCS, and NIH-3T3 artificial antigen-presenting cells (AAPC), described previously (6), were cultured in DMEM supplemented with 10% heat-inactivated donor calf serum. All media were supplemented with 2 mmol/L L-glutamine (Life Technologies), 100 units/mL penicillin, and 100 Ag/mL streptomycin (Life Technologies). Where indicated, medium was supplemented with 10 ng/mL interleukin 15 (IL-15; R&D Systems).
Construction of second-generation CAR fusion genes. Construction of the 19z1 and Pz1 scFv-~chain fusion proteins have been previously published (6, 8) . The resulting fusion genes were cloned into the SFG retroviral vector (9) . VSV-G pseudotyped retroviral supernatants derived from transduced gpg29 fibroblasts were used to construct stable PG-13 gibbon ape leukemia virus (GaLV) envelope-pseudotyped retroviral producing cell lines using polybrene (Sigma) as described previously (8) . All second-generation fusion receptors contain the scFv derived from 19z1. Human CD28, DAP10, 4-1BB, and OX40 coding regions were PCR amplified from a human activated T-cell cDNA library, and subcloned into the TopoTA PCR 2.1 cloning vector (Invitrogen). All receptor constructs were generated using overlapping PCR. The resulting cassettes were designed to facilitate the exchange of the transmembrane and signaling domains of the 19z1 construct by NotI/ BamHI restriction sites encoded in flanking primers.
Retroviral transduction and expansion of human T lymphocytes. Retroviral transduction of healthy donor T cells, obtained under institutional review board -approved protocol 90-095, is described elsewhere (8) . For ex vivo expansion studies and cytokine release assays, transduced T cells were cocultured for 7 days after retroviral transduction in 24-well tissue culture plates (Falcon, Becton Dickinson) with confluent NIH 3T3 AAPCs in RPMI medium supplemented with 10% FCS, L-glutamine, streptomycin, and penicillin, with no added cytokines. For in vivo experiments, transduced T cells were injected after expansion on 3T3(CD19/CD80) or, for the Pz1 + T cell control, 3T3[prostate-specific membrane antigen (PSMA)/CD80] AAPCs in RPMI medium as above, supplemented with 20 IU IL-2/mL and 10 ng/mL IL-15. For mice treated with multiple injections of modified T cells for 4 weeks, CAR + T cells were generated by weekly restimulation on AAPCs as described above.
Western blot analysis. Western blot analysis of T-cell lysates under reducing conditions with 0.1 mol/L DTT (Sigma) was done as previously described (10) . Briefly, transduced T cells were washed in PBS and resuspended in radioimmunoprecipitation assay buffer (Boston Bioproducts) with mini complete protease inhibitor as per the manufacturer's instructions (Roche Diagnostics). Resulting proteins were separated on 12% SDS-PAGE mini gels (Bio-Rad) after the addition of 6Â reducing loading buffer (Boston Bioproducts) and heating at 100jC for 10 min. Separated proteins were subsequently transferred to Immobilon membranes and probed using an anti-human CD3~chain monoclonal antibody (BD Biosciences). Antibody binding was detected by probing the blot with goat anti-mouse horse radish peroxidase -conjugated antibody followed by luminescent detection using Western Lighting Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences) as per the manufacturer's instructions.
Cytotoxicity assays. We determined the cytotoxic activity of transduced T cells by standard 51 Cr release assays as described elsewhere (8) . Briefly, transduced T cells were assessed by fluorescence-activated cell sorting analysis for CAR expression as well as CD4:CD8 ratio on day 4 after transduction. NALM-6 tumor cells were labeled with 51 Cr for 1 h at 37jC, washed with RPMI medium supplemented with 10% FCS, and resuspended in the same medium at a concentration of 1 Â 10 5 tumor cells/mL. Transduced T cells were added to tumor cells at varying effector to target cell ratios in 96-well tissue culture plates in a final volume of 200 AL, and incubated for 4 h at 37jC. Thereafter, 30 AL of supernatant from each well was analyzed using Lumaplate-96 microplates (Packard Bioscience) by a Top Count NXT microplate scintillation counter (Packard Bioscience). Effector cell number in all assays was calculated based on the total number of CD8 + CAR + T cells. Cytokine detection assays. Cytokine assays were done per manufacturer's specifications using the multiplex Human Cytokine Detection System (Upstate, Inc.). Luminescence was assessed using the Luminex IS100 system and analyzed for cytokine concentration using IS 2.2 software (Luminex Corp.).
Flow cytometry. We did flow cytometry using a FACScan cytometer with Cellquest software (BD Biosciences). Cells were labeled with either phycoerythrin-conjugated, CAR-specific polyclonal goat antibody (Caltag Laboratories) or phycoerythrin-labeled anti-human CD8 and FITClabeled anti-human CD4 monoclonal antibodies (Caltag Laboratories).
Retroviral transduction of NALM-6 tumor cells with GFP-FFLuc. The GFP-FFLuc gene (Clontech Laboratories) was subcloned into the SFG retroviral vector. VSV-G pseudotyped retroviral supernatants derived from gpg29 fibroblasts transduced with the resulting SFG (GFP-FFLuc) plasmid were used to transduce NALM-6 tumor cells as described elsewhere (10) . Resulting tumor cells were sorted by fluorescenceactivated cell sorting for GFP expression.
In vivo SCID-Beige mouse tumor models. We inoculated 8-to 12-week-old FOX CHASE C.B-17 (SCID-Beige) mice (Taconic) with tumor cells by tail vein injection. We subsequently treated mice by tail vein injection with transduced T cells. In the Raji tumor model, mice were injected by tail vein with 5 Â 10 5 Raji tumor cells on day 1, and on day 6 were treated with a single i.v. dose of 1 Â 10 7 CAR + T cells. In the NALM-6 upfront treatment tumor model, mice were injected by tail vein on day 1 with 1 Â 10 6 NALM-6 tumor cells, and on days 2 to 4 were injected i.v. with 1 Â 10 7 CAR + T cells daily. In the weekly treatment model, mice were inoculated with NALM-6 tumor cells on day 1, and subsequently treated with i. In vivo bioluminescence of NALM-6 tumors. Bioluminescence imaging was done using Xenogen IVIS Imaging System (Xenogen) with Living Image software (Xenogen) for acquisition of imaging data sets. Mice were infused by i.p. injection with 150 mg/kg D-luciferin (Xenogen) suspended in 200 AL PBS. Ten minutes later, mice were imaged while under 2% isoflurane anesthesia. Image acquisition was done on a 15-or 25-cm field of view at medium binning level for 0.5-to 3-min exposure time. Both dorsal and ventral views were obtained on all animals. Tumor bulk, as determined by IVIS imaging, was assessed as described previously (11) .
Histologic analysis of mouse tissue sections. Mouse tissues were fixed in 10% buffered formalin phosphate (Fisher Scientific). Osseous samples (head with brain, vertebral column with spinal cord, and hind limbs) were fixed and decalcified in SurgiPath Decalcifier I (SurgiPath Medical Industries) as per the manufacturer's specifications. All tissues were processed by routine methods and embedded in paraffin wax. Five-micrometer sections were stained with H&E (Poly Scientific).
Statistics. Statistical analysis of survival data by log-rank analysis was obtained using GB-STAT software (Dynamic Microsystems).
Results
Construction of second-generation costimulatory CARs. We have previously shown that T cells which express the firstgeneration 19z1 CAR successfully eradicate systemic CD80/ CD86 + Raji tumor in SCID-Beige mice. However, in the same report, we further show the inability of 19z1 + T cells to fully eradicate systemic NALM-6 tumors, which fail to express the costimulatory CD80 and CD86 ligands. The genetic modification of NALM-6 tumors to express CD80 allowed for the complete eradication of tumor in a significant number of treated mice (6) consistent with the notion that in vivo T-cell costimulation enhances the antitumor efficacy of tumorspecific T cells.
Because most B-cell tumors fail to express costimulatory ligands, we addressed this limitation of our treatment strategy by constructing a series of second-generation CARs designed to deliver an additional costimulatory signal in the absence of exogenous costimulatory ligand by inserting the transmembrane and cytoplasmic signaling domains of the CD28, DAP10, and 4-1BB costimulatory receptors into the 19z1 CAR (Fig. 1A) . Alternative DAP-10 -and 4-1BB -containing receptors, as well as the OX-40 -containing CAR, were designed to contain the CD8 transmembrane domain from the original 19z1 construct to assess whether this CAR design could enhance costimulatory signaling. Finally, we also assessed whether placing the DAP-10 signaling domain either proximal or distal to the~chain signaling domain improved CAR function.
T cells from healthy human donors were retrovirally transduced to express these CAR constructs. T-cell transduction efficiency, as assessed by flow cytometric analysis, ranged from 50% to 80% (data not shown). Western blot analysis of transduced T cells, normalized to the CAR + fraction, showed comparable levels of CAR proteins present at the predicted molecular weights (Fig. 1B) .
To verify that second-generation CARs when expressed in human T cells retained the ability to lyse CD19 + tumor cells in vitro, we conducted standard 4 h 51 Cr release assays using transduced healthy donor T cells targeting 51 Cr-labeled CD19 + NALM-6 tumor cells (Fig. 1C) . Effector to target ratio between different CAR constructs was normalized to the CD8 + CAR + T-cell population. All tested CARs, with the exception of the Pz1 + T-cell control, specific to the PSMA, were able to mediate tumor cell lysis equally well when compared with the firstgeneration 19z1 CAR.
Characterization of second-generation CAR costimulatory function. We have previously generated a series of AAPCs derived from NIH-3T3 murine fibroblasts genetically engineered to express either CD19 alone [3T3(CD19)] or both CD19 and CD80 [3T3(CD19/CD80); ref . 6] . When cocultured To assess CAR-mediated T-cell proliferation, transduced T cells were cocultured on both 3T3(CD19) and 3T3(CD19/ CD80) AAPCs in the absence of exogenous cytokine. CAR + T-cell number was determined after coculture on 3T3(CD19) and 3T3(CD19/CD80) AAPCs ( Fig. 2A) Fig. 2B) and IFN-g (Fig. 2C) when compared with the first-generation 19z1 CAR as well as the other six tested secondgeneration CARs. These data further confirm the ability of the 19-28z CAR to elicit a costimulatory signal independent of exogenous costimulatory ligand. Significantly, 4-1BB and DAP-10 constructs containing either the native or CD8 transmembrane domains showed no significant differences in function, and in the setting of the DAP-10 constructs, no differences in function were observed when the signaling domain was placed either proximal or distal to the~chain.
In vivo antitumor activity of alternative costimulatory CARs. To define the in vivo costimulatory activity of the 19- (Fig. 3A) . We next compared the same treatment groups (19z1 versus 19-28z) in mice bearing systemic NALM-6 tumor, which fails to express the CD80 and CD86 costimulatory ligands. We observed improved antitumor efficacy in the 19-28z treatment group (Fig. 3B) . However, the improved long-term overall survival was modest (0 of 15 19z1 + T cell -treated mice versus 3 of 17 or 18% of 19-28z + T celltreated mice; P < 0.03). Treatment with 19(4-1BB)z + and 19(4-1BBic)z + T cells enhanced survival when compared with mice treated with the control Pz1 + T cells, but overall survival was similar to 19z1 + T cell -treated mice, with no long-term surviving mice (data not shown). Fluorescence-activated cell sorting analysis of single-cell suspensions of tissues derived from mice that failed 19-28z + T cell treatment showed persistent expression of CD19 on the tumor cells, ruling out the possibility that down-regulation of the CD19 target antigen was a source of treatment failure (data not shown).
Repeated administration of CD19-targeted T cells enhances complete NALM-6 tumor eradication. Using bioluminescent imaging of treated SCID-Beige mice bearing NALM-6(GFPFFLuc) tumors, we found a 10-to 14-day delay of tumor progression after 19z1 + T-cell therapy when compared with Pz1 + T-cell therapy (Fig. 4A-B) . A similar delay of tumor progression was seen after 19-28z + T-cell therapy in mice with relapsed disease (data not shown). Fluorescence-activated cell sorting analysis of single-cell suspensions derived from tissues of 19-28z + T cell -treated tumor-bearing mice confirmed a short in vivo T-cell survival (data not shown), consistent with previously published data demonstrating limited in vivo survival of human T cells in an immunocompromised murine host (11 -14) .
To assess whether enhanced in vivo T-cell persistence promoted long-term survival, we generated a sustained in vivo population of tumor-targeted T cells in NALM-6 tumor bearing SCID-Beige mice by injecting CAR + T cells weekly for 4 weeks. The incidence of long-term survival with 19-28z + T-cell therapy increased from 18% as seen in the upfront daily Â3 treatment schedule to 44% in the weekly treatment schedule (Figs. 3B and 4C, respectively). Consistent with an additive effect of in vivo T-cell persistence and costimulation, we found superior antitumor activity of 19-28z + T cells, when compared with + T cells, as shown by 44% versus 10% long-term survival (P < 0.002), using this weekly T-cell dosing schedule (Fig. 4C) .
CD19-targeted T cells eradicate NALM-6 tumor cells at disparate anatomic sites in SCID-Beige mice after adoptive T-cell therapy. Despite improved survival with the weekly T-cell dosing treatment schedule, 56% of [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] + T cell -treated mice ultimately failed therapy. To assess whether these mice developed persistent or recurrent tumor in consistent anatomic sites potentially restricted from T-cell penetration or detection, we monitored in vivo NALM-6(GFP-FFLuc) tumor progression by weekly bioluminescent (IVIS) imaging in the setting of the weekly T-cell treatment regimen. In these studies, all control mice treated weekly with Pz1 + T cells showed diffuse tumor progression at multiple sites over the treatment period (Fig. 5A) . By weekly IVIS monitoring of the 19z1 + T cell -treated mice, 40% (4 of 10) had no detectable disease upon completion of therapy (day 28). In the nine mice that developed progressive disease in this treatment group, initial disease persistence or relapse was noted at distinct anatomic sites in different mice, including the bone marrow (n = 2; Fig. 5B ), the periodontal region (n = 3), the spleen/calvarium (n = 1), the abdomen (n = 1), and the CNS/calvarium (n = 1). Overall, 69% (11 of 16) of mice treated with weekly 19-28z + T-cell infusions showed no evidence of disease by weekly IVIS imaging upon completion of therapy. The 56% (9 of 16) of 19-28z + T cell -treated mice, which ultimately failed therapy, likewise showed detectable disease at disparate anatomic sites, including the spleen (n = 1; Fig. 5C ), the CNS/calvarium (n = 2; Fig. 5D ), the periodontal region (n = 4; Fig. 5E ), and the bone marrow (n = 2; Fig. 5F ). Significantly, persistent disease in the periodontal region, despite ongoing T-cell therapy, was noted in 30% of 19z1-treated mice, and 25% of 19-28z -treated mice, accounting for a large majority of the mice with evidence of disease upon completion of treatment. The presence of tumor as assessed by bioluminescent imaging in 19-28z + T cell -treated mice was subsequently confirmed by histologic analysis, demonstrating NALM-6 tumor infiltration in the bone marrow (Fig. 6A-B) , the spleen (Fig. 6C-D) , and the periodontal region (Fig. 6E-F) .
Discussion
The successful clinical application of adoptive therapy of cancer with genetically targeted T cells requires both a better understanding of the in vivo biology of genetically modified T cells, as well as innovative means of enhancing the in vivo potency of these T cells. In this report, we use the clinically relevant NALM-6 systemic murine model of human B-cell ALL, which involves the bone marrow and CNS, and lacks expression of costimulatory ligands, features common to human pre -B-cell leukemia. Using this model, we studied in vivo T-cell function by assessing the roles of costimulation, persistence, and homing in the successful eradication of systemic disease. CD3~chain signaling through either the native TCR or a first-generation CAR results in an initial T-cell activation termed signal 1. For subsequent proliferation to occur, a costimulatory signal, or signal 2, is often required, which is mediated through the binding of costimulatory receptors expressed by the T cell to cognate costimulatory ligands expressed on the APC or target cell (15 -18) . We have previously shown that NALM-6 tumors genetically engineered to express the CD80 costimulatory ligand enhanced complete tumor eradication in mice treated with the first-generation 19z1 CAR (6) . Although signal 1 alone is capable of triggering T cell -mediated cytolysis and is sufficient to eradicate tumor in the setting of suitably high numbers of adoptively transferred T cells (11) , the generation of the large T cell numbers required to achieve complete tumor eradication with T cells that express first-generation CARs is less practical in the clinical setting. Therefore, because most tumors fail to express costimulatory ligands, successful application of this treatment approach has required the development of second-generation CARs capable of delivering both primary as well as costimulatory signals to the modified T cell upon engagement with the targeted tumor antigen (12 -14, 19 -24) .
To address this limitation, we constructed a series of secondgeneration CARs containing the cytoplasmic signaling domains of known T-cell costimulatory receptors, which mediate IL-2 secretion, including CD28 (25), 27) , , and 4-1BB (16, 29) . Our studies presented here show that of these signaling domains, only the inclusion of the CD28 transmembrane and signaling domains into the 19z1 CAR enhanced both T-cell proliferation and cytokine secretion in vitro in the absence of exogenous costimulatory ligands. These data are consistent with the ability of the 19-28z receptor to provide both primary and costimulatory signals to the T cell.
Several groups have previously published data on the in vitro activity of human T cells modified with various secondgeneration CARs (19 -22, 24, 30) . The in vitro data presented here are consistent with previously published studies investigating the ability of CARs containing the CD28 cytoplasmic domain to costimulate T cells independent of exogenous costimulation. Discrepancies between our findings and those published by others demonstrating enhanced costimulation in second-generation CARs bearing the cytoplasmic signaling domains of the 4-1BB and OX-40 receptors (21, 22) may be due to both differences in target antigen and CAR construction, implying a critical role of extracellular CAR design to signaling function (31) . Significantly, modification of 4-1BB and DAP-10 CAR constructs by either altering the transmembrane domain or the location of the DAP10 costimulatory signaling domain failed to enhance CAR function. More recently, other investigators have published promising in vitro data describing ''third-generation'' CARs, which incorporate the cytoplasmic domains of other T-cell signaling ligands in CD28-containing second-generation CARs including OX-40 (24) and Lck (32) . However, to date, no in vivo data has been published using these constructs.
Although we and others have previously published data on the in vitro activity of human T cells modified with various second-generation CARs, few have explored the activity of these modified T cells in vivo (12 -14, 23) . To date, only two studies have directly compared the activity of T cells transduced with a first-generation CAR to T cells expressing a second-generation CAR. Teng et al. (13) + T cells. However, this improved long-term survival was modest (Fig. 3B) . We postulated that treatment failure in this model was due to overall poor in vivo survival of human T cells in the SCID-Beige mouse. Consistent with the notion that in vivo modified T-cell persistence is critical to the complete eradication of tumor, we found that further prolonging T-cell presence in tumor bearing mice through weekly injections of modified T cells delayed tumor progression in both 19z1 + and 19-28z + T cell -treated mice (Fig. 4C ). This modified treatment strategy markedly improved the long-term survival of 19-28z + T cell -treated mice when compared with the upfront 19-28z + T-cell treatment schema (Figs. 3B and 4C). Our modified treatment strategy further highlights the additional significance of in vivo costimulation in tumor eradication as shown by the improved long-term survival of mice treated with weekly infusions of 19-28z + T cells when compared with mice treated with weekly infusions of 19z1 + T cells. The exact mechanism(s) whereby 19-28z CAR signaling enhances T-cell antitumor activity remains speculative. Although in vivo costimulation through the 19-28z CAR may enhance T-cell survival, enhanced antitumor activity may also be due to superior in vivo proliferation. Alternatively, costimulatory signaling through the 19-28z CAR may avert T-cell anergy, allowing for the improved serial killing of tumor cells by each T cell. Further studies are needed to better elucidate these potential mechanisms.
Using IVIS bioluminescent imaging, we found that a majority of mice that failed therapy had no detectable evidence of tumor after the completion of weekly T-cell therapy, but only thereafter relapsed at various anatomic sites, including the bone marrow, the spleen, periodontal area, and the CNS/ calvarium (Fig. 5) . In light of the disparate patterns of disease relapse after treatment, these data are consistent with the notion that modified T cells successfully home to multiple sites of tumor involvement. Furthermore, given the fact that tumor relapse occurred in the majority of mice only upon cessation of therapy, our data suggests that treatment failure in this tumor model may be attributable, in part, to a suboptimal duration of T-cell therapy. Finally, although our data support the notion of successful homing of CAR-modified T cells to systemic anatomic sites in the setting of a hematologic malignancy, it remains to be seen if similar successful homing of CARmodified T cells occurs in the setting of solid tumor metastases.
One anatomic exception to successful T-cell homing is in the periodontal region where persistent disease was noted in 30% of weekly 19z1 + T cell and 25% of weekly 19-28z + T-cell treated mice despite ongoing therapy. Interestingly, periodontal tumor infiltration in a xenograft model of the PC-3 human prostate cancer cell line has been previously reported and attributed by the authors of this study to the proliferative microenvironment generated by mouse incisors, which continuously erupt (34) . Because the periodontal region is not a common site of ALL or prostate cancer relapse in the clinical setting, the significance of this finding is less likely to be clinically relevant, and more likely to be a peculiarity of xenogeneic murine tumor models.
In conclusion, the data presented here have several potential implications for the use of adoptive immunotherapy using genetically targeted T cells in cancer therapy. First, the data show superior in vivo antitumor activity of T cells modified to express a CD28-containing costimulatory secondgeneration CAR in the setting of tumor cells, which fail to express costimulatory ligands. Second, our findings strongly support the view that in vivo T-cell persistence is critical to the successful application of this treatment strategy. Third, our data show that engineered T cells successfully home to multiple systemic sites of tumor involvement and is therefore an unlikely source of treatment failure in most mice. Finally, these studies support the continued use of xenogeneic tumor models in the study of in vivo human T-cell biology after adoptive therapy.
Based on these and other (6) preclinical findings, we are planning to conduct a clinical trial treating chemotherapyrefractory chronic lymphocytic leukemia patients with autologous 19-28z + T cells. Furthermore, the significance of T-cell persistence as shown here predicts that repeated T-cell infusions in the setting of poor in vivo T-cell survival will likely enhance the therapeutic efficacy of this treatment strategy, a hypothesis we plan to address in subsequent clinical trials.
